The ESMO Gastrointestinal Cancers Congress 2025 programme is online!
The ESMO Gastrointestinal Cancers Congress is a place for the global GI oncology community to present and discuss impactful new research data in gastrointestinal oncology, in a comprehensive programme also rich in high-quality educational sessions. The congress offers excellent networking opportunities in an international environment.
Learning objectives
- To update oncology health care professionals on recent developments in state of the art management of patients with gastrointestinal malignancies
- To highlight breakthroughs in the molecular prevention, diagnosis and precision therapy of gastrointestinal cancers
- To provide in-depth knowledge in controversy areas of gastrointestinal oncology
- To provide expert insights in research methodology, patient advocacy, policy and regulation
Accreditation
ESMO-MORA: The ESMO Gastrointestinal Cancers 2025 Congress programme will be submitted for ESMO-MORA category 1 points accreditation. . Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
Disclaimer
ESMO is a scientific and professional, non-political and non-religious organisation. ESMO will not accept responsibility for any comments or remarks made during any of our events by session chairs, invited speakers, presenters, members or any other contributor, formally or informally, which might cause offence or be perceived as being biased.
The experts invited by ESMO as abstract Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.